However, after 2013, three-drug regimen consisting of a nucleoside reverse-transcriptase inhibitor (NTRI), (tenofovir plus emtricitabine), along with a third drug, either an integrase strand transfer inhibitor,
raltegravir or a boosted protease inhibitor,
darunavir/ritonavir is recommended for PEP.
Ideally, NTRI is an important component of the regimen because if HIV infects a cell, it first attaches to and fuses with the host cell.